Effects of Puff Adder Venom on the Coagulation Mechanism

Louise L. Phillips; H. J Weiss; N. P Christy

doi:10.1055/s-0038-1649128

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1973; 30(03): 499-508
DOI: 10.1055/s-0038-1649128

Original Article

Schattauer GmbH

Effects of Puff Adder Venom on the Coagulation Mechanism

II. In Vitro

Authors

Louise L. Phillips

¹Department of Medicine, The Roosevelt Hospital and College of Physicians and Surgeons, Columbia University New York, N.Y.
H. J Weiss

¹Department of Medicine, The Roosevelt Hospital and College of Physicians and Surgeons, Columbia University New York, N.Y.
N. P Christy

¹Department of Medicine, The Roosevelt Hospital and College of Physicians and Surgeons, Columbia University New York, N.Y.

Abstract

Summary

Studies of the in vitro effects of puff adder venom (Bitis arietans) on the coagulation system of human plasma have suggested this venom activates factor XI. Incubation with the venom results in a prolongation of the partial thromboplastin times in glass which is associated with a depletion of factors V, VIII, and fibrinogen. The latter may be due to the proteolytic properties of the venom. Soluble fibrin monomer complexes are formed rapidly after addition of the venom to normal plasma. The venom also causes platelet aggregation which is not inhibited by heparin.

Full Text

References

References
1 Aravindakshan I, and Branganca B. M. 1961; Studies on Phospholipid structures in mitochondria of animals injected with cobra venom and phospholipase A. Biochemical Journal 79: 84.
2 Christensen P. A. 1955 South African Snake Venom and Antivenoms. South African Institute of Medical Research, Johannesburg.
3 Condrea E, de Vries A, and Mager J. 1937; Action of snake venom phospholipase A on free and lipoprotein bound Phospholipids. Biochemica, Biophysica Acta 58: 389.
4 Eagle H. 1937; The coagulation of blood by snake venoms and its physiologic significance. Journal of Experimental Medicine 65: 613.
5 Fletcher A. P, Alkjaersig H, and Sherry S. 1962; Pathogenesis of the coagulation defect developing during pathological plasma proteolytic (fibrinogen) states. I. The Significance of fibrinogen proteolysis and circulating fibrinogen breakdown products. Journal of Clinical Investigation 41: 896.
6 Nye S. W, Graham J. B, and Brinkhous K. 1963; The partial thromboplastin time as a screening test for the detection of latent bleeders. American Journal of Medical Science 243: 279.
7 Phillips L. L, and Skrodelis V. 1958; The fibrinolytic enzyme system in normal, hemorrhagic and disease states. Journal of Clinical Investigation 37: 965.
8 Phillips L. L, Weiss H. J, Pessar L, and Christy N. P. 1973; Effects of Puff Adder Venom on the Coagulation Mechanism. I. In Vivo. Toxicon II: 423.
9 Proctor R. R, and Rapaport S. I. 1961; The partial thromboplastin time with kaolin: A simple screening test for first stage plasma clotting factor deficiencies. American Journal of Clinical Pathology 36: 212.
10 Quick A. J. 1951. The Physiology and Pathology of Hemostasie. Lea and Febiger; Philadelphia:
11 Ratnoff O. D, and Menzie C. 1951; A new method for the determination of fibrinogen in small samples of plasma. Journal of Laboratory and Clinical Medicine 37: 316.
12 Rosano L, Phillips L. L, and Davidson Jr. E. C. 1969; Studies of hypercoagulability induced by injection of Russell’s viper venom. Federal Proceedings 28: 442.
13 Seaman A. J. 1970; The recognition of intravascular clotting. The plasma protamine paracoagulation test. Archives of Internal Medicine 125: 1016.
14 Tocantins L. M, and Kazal L. A. Eds. 1964. Blood Coagulation, Hemorrhage and Thrombosis. Grune and Stratton; New York:
15 Weiss H. J, Aledort L. M, and Kochwa S. 1968; The effect of salicylates on the hemostatic properties of platelets. Journal of Clinical Investigation 47: 2169.
16 Weiss H. J, Phillips L. L, Hopewell W. S, Phillips G, Christy N. P, and Nitti J. F. 1973; Heparin therapy in a patient bitten by a saw-scaled viper (Echis carinatus), a snake whose venom activates prothrombin. The American Journal of Medicine 54: 653.